- All sections
- A - Human necessities
- A61K - Preparations for medical, dental or toiletry purposes
- A61K 31/505 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
Patent holdings for IPC class A61K 31/505
Total number of patents in this class: 5132
10-year publication summary
|
394
|
346
|
340
|
321
|
348
|
347
|
361
|
296
|
270
|
69
|
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Novartis AG | 11238 |
84 |
| Bristol-myers Squibb Company | 5080 |
79 |
| Rigel Pharmaceuticals, Inc. | 613 |
69 |
| Boehringer Ingelheim International GmbH | 4629 |
64 |
| Merck Sharp & Dohme LLC | 3689 |
64 |
| Janssen Pharmaceutica N.V. | 3839 |
54 |
| Janssen Sciences Ireland Unlimited Company | 431 |
52 |
| Acetylon Pharmaceuticals, Inc. | 70 |
46 |
| AstraZeneca AB | 3042 |
45 |
| Takeda Pharmaceutical Company Limited | 2961 |
45 |
| Merck Sharp & Dohme Corp. | 2247 |
43 |
| Amarin Pharmaceuticals Ireland Limited | 267 |
41 |
| Abbvie Inc. | 1808 |
38 |
| Janssen Sciences Ireland UC | 256 |
37 |
| F. Hoffmann-La Roche AG | 7958 |
36 |
| Merck Patent GmbH | 5909 |
29 |
| FUJIFILM Corporation | 27102 |
28 |
| Dana-Farber Cancer Institute, Inc. | 2455 |
28 |
| The Regents of the University of California | 18943 |
26 |
| Signal Pharmaceuticals, LLC | 188 |
25 |
| Other owners | 4199 |